Loading…
Lyfe Rx was cited for unlawfully selling unapproved and misbranded compounded drugs (semaglutide and tirzepatide) over the internet. The company's website made false or misleading claims stating the products were "clinically proven" for weight loss, implying they were equivalent to FDA-approved versions when compounded drugs are not FDA-approved, thereby violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. These misbranded products were introduced into interstate commerce in violation of section 301(a) of the FDCA.